|
Regeneron/NIAID
|
REGN-COV2 (REGN10933 + REGN10987; human IgG1 mAbs targeting S protein epitope)
|
Phase 2/3
|
NCT04452318
|
2,000 healthy adults with infected people in household
|
|
Regeneron/NIAID
|
REGN-COV2
|
Phase 2/3
|
NCT04426695
|
2,970 hospitalized adults with COVID-19
|
|
Regeneron/NIAID
|
REGN-COV2
|
Phase 1/2
|
NCT04425629
|
2,104 ambulatory patients with COVID-19
|
|
AbCellera/Eli Lilly/NIH
|
LY3819253 or LY3819253 + LY3832479 (human IgG1 mAbs targeting S protein epitope)
|
Phase 3
|
NCT04427501
|
800 patients with mild to moderate COVID-19
|
|
AbCellera/Eli Lilly/NIH
|
LY3819253 or LY3819253 + LY3832479
|
Phase 3
|
NCT04497987
|
2,400 healthy staff or residents of skilled nursing facilities
|
|
AbCellera/Eli Lilly/NIH
|
LY3819253 versus remdesivir (small-molecule nucleotide analog antiviral that blocks viral RNA polymerase)
|
Phase 3
|
NCT04501978
|
10,000 hospitalized patients
|
|
Vir Biotechnology/GlaxoSmithKline
|
VIR-7831/GSK4182136 (human IgG1 mAb targeting S protein epitope)
|
Phase 3
|
NCT04545060
|
1,360 non-hospitalized patients with COVID-19 at high risk
|
|
BeiGene/Singlomics/Peking University
|
BGB-DXP593 (human IgG1 mAb targeting S protein epitope)
|
Phase 2
|
NCT04551898
|
180 patients with mild to moderate COVID-19
|
|
BeiGene/Singlomics/Peking University
|
BGB-DXP593
|
Phase 1
|
NCT045332294
|
30 healthy adults 18–60 years olds
|
|
Junshi Biosciences/Institute of Microbiology, Chinese Academy
|
JS016 (human mAb targeting S protein epitope)
|
Phase 1
|
NCT04441918
|
40 healthy participants 15–45 years old
|
|
Tychan
|
TY027
|
Phase 1
|
NCT04429529
|
32 healthy adults 21–50 years old
|
|
Celltrion
|
CT-P59 (human mAb targeting S protein epitope)
|
Phase 1
|
NCT04525079
|
32 healthy adults 19–55 years old
|
|
Brii Bio/TSB Therapeutics/Tsinghua University
|
BRII-196 (human mAb targeting S protein epitope)
|
Phase 1
|
NCT04479631
|
12 healthy adults 18–49 years old
|
|
Brii Bio/TSB Therapeutics/Tsinghua University
|
BRII-198 (human mAb targeting S protein epitope)
|
Phase 1
|
NCT04479644
|
12 healthy adults 18–49 years old
|
|
Sinocelltech/Chinese Academy of Sciences
|
SCTA01 (humanized mAb targeting S protein epitopes)
|
Phase 1
|
NCT04483375
|
33 healthy adults
|
|
Mabwell (Shanghai) Bioscience
|
MW33 (human mAb targeting S protein epitope)
|
Phase 1
|
NCT05433048
|
42 healthy adults 18–45 years old
|
|
Sorrento/Mount Sinai
|
COVI-GUARD/STI-1499 (human mAb targeting S1 subunit of S protein)
|
Phase 1
|
NCT04454398
|
33 hospitalized patients with moderate COVID-19
|
|
AstraZeneca/Vanderbilt
|
AZD8895 + AZD1061 (IgG1 human mAbs targeting S protein epitopes)
|
Phase 1
|
NCT04507256
|
48 healthy adults 18–55 years old
|
|
Hengenix Biotech
|
HLX70 (human mAb targeting S protein epitope)
|
Phase 1
|
NCT04561076
|
24 healthy adults 18–60 years old
|
